Although Argenica Therapeutics Ltd.’s stroke drug, ARG-007, saw mixed results in top-line phase II data, new data in functional outcomes studies showed signs the drug helped patients think more clearly, regain independence, and enjoy a better quality of life after stroke.
Although Argenica Therapeutics Ltd.’s stroke drug, ARG-007, saw mixed results in top-line phase II data, new data in functional outcomes studies showed signs the drug helped patients think more clearly, regain independence, and enjoy a better quality of life after stroke.
Ischemic stroke triggers a strong neuroinflammatory response, with microglial activation and neutrophil infiltration contributing to blood-brain barrier disruption and worsening neuronal damage.
Endoplasmic reticulum oxidoreductase 1 (ERO1) has traditionally been associated with proper protein folding in the endoplasmic reticulum, but it has recently been linked to platelet activation and aggregation in arterial thrombosis and ischemic stroke.
Stroke is the third leading cause of disability worldwide, and its incidence is expected to increase as the global population ages. Idebenone can promote recovery after stroke, but it is less effective during the acute phase of stroke.
Anaconda Biomed SL recently received CE mark for the Ana5 funnel catheter, designed to improve mechanical thrombectomy in the treatment of acute ischemic stroke. The company hopes that the device, which has a vessel-matching diameter funnel to maximize the capture of blood clots, could be the holy grail in mechanical thrombectomy.
Stroke accounts for nearly 12% of all deaths worldwide, making it the second leading cause of death. In acute ischemic stroke, the ischemia and subsequent return of blood flow create oxidative and nitrosative stress that can overwhelm neurons and disable important circuitry.
Following a stroke, multiple immune cell types contribute to the neuroinflammatory response, with T cells being among the most consistently associated with both the initial and secondary phases of brain injury.
Scientists at Beijing Wehand-Bio Pharmaceutical Co. Ltd. and Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have synthesized phthalazinone compounds with neuroprotective effects reported to be useful for the treatment of hemorrhagic and ischemic stroke.
